EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Tóm tắt
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field.
An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items.
The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high.
These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost.
Từ khóa
Tài liệu tham khảo
Lau, 2015, APLAR rheumatoid arthritis treatment recommendations, Int J Rheum Dis, 18, 685, 10.1111/1756-185X.12754
Bergstra, 2018, Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry, Ann Rheum Dis, 77, 1413, 10.1136/annrheumdis-2018-213289
Holloway K , van Dijk L . The world medicines situation 2011. rational use of medicines. WHO/EMP/MIE/2011.2.2. Geneva: World Health Organzization, 2011.
OCEBM Levels of Evidence Working Group . Oxford centre for evidence-based medicine. The Oxford 2011 Levels of Evidence, 2011.
Jani, 2019, Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?, Curr Opin Rheumatol, 31, 285, 10.1097/BOR.0000000000000598
Taibanguay, 2019, Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial, Patient Prefer Adherence, 13, 119, 10.2147/PPA.S192008
Solomon, 2018, Benefits and sustainability of a learning collaborative for implementation of Treat-to-Target in rheumatoid arthritis: results of a cluster-randomized controlled phase II clinical trial, Arthritis Care Res, 70, 1551, 10.1002/acr.23508
Scotti, 2018, Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis, Semin Arthritis Rheum, 48, 28, 10.1016/j.semarthrit.2018.01.003
Verden, 2018, Analysis of spontaneous Postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors, Drug Saf, 41, 357, 10.1007/s40264-017-0622-2
Widdifield, 2011, Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective, Arthritis Care Res, 63, 53, 10.1002/acr.20304
Memel, 2003, General practitioner and specialist care: the perceptions of people with rheumatoid arthritis, Primary Health Care Research Development, 4, 29, 10.1191/1463423603pc120oa
Frisell, 2019, Comment on: comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply, Rheumatology, 58, 1510, 10.1093/rheumatology/kez120
Smolen, 2017, Brief report: remission rates with tofacitinib treatment in rheumatoid arthritis: a comparison of various remission criteria, Arthritis Rheumatol, 69, 728, 10.1002/art.39996
Kameda, 2019, Japan College of rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis, Mod Rheumatol, 29, 31, 10.1080/14397595.2018.1472358
Lund Hetland, 2019, A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy and safety results of the NORD-STAR trial, Arthritis Rheumatol, 71, 5237
Van Der Heijde, 1990, Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up, The Lancet, 335, 539, 10.1016/0140-6736(90)90771-V
Wollenhaupt, 2019, Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study, Arthritis Res Ther, 21, 89, 10.1186/s13075-019-1866-2
Taylor, 2019, Cardiovascular safety during treatment with Baricitinib in rheumatoid arthritis, Arthritis Rheumatol, 71, 1042, 10.1002/art.40841
Fleischmann, 2019, Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial, Arthritis Rheumatol, 71, 1788, 10.1002/art.41032
Fleischmann, 2017, Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (oral strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial, Lancet, 390, 457, 10.1016/S0140-6736(17)31618-5
Genovese, 2017, Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease‐modifying antirheumatic drugs in the treatment of moderate‐to‐severe rheumatoid arthritis, Arthritis & Rheumatology, 69, 932, 10.1002/art.40054
RINVOQ (upadacitinib) . Highlights of prescribing information, 2019. Available: https://www accessdata fda gov/drugsatfda_docs/label/2019/211675s000lbl pdf [Accessed 17 Aug 2019].
US Food and Drug Administration . Center for Drug Evaluation and Research. Statistical Review - Clinical Studies - Olumiant (baricitinib), 2019. Available: https://www accessdata fda gov/drugsatfda_docs/nda/2018/207924Orig1s000StatR pdf
European Medicines Agency (EMA) . Xeljanz to be used with caution for all patients at high risk of blood clots (EMA/584781/2019), 2019. Available: https://www ema europa eu/en/documents/referral/xeljanz-article-20-procedure-xeljanz-be-used-caution-all-patients-high-risk-blood-clots_en pdf
Pfizer . Safety study of tofacitinib versus tumor necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis, 2019. Available: https://clinicaltrials.gov/ct2/show/NCT02092467?term=study+A3921133&draw=1&rank=1 [Accessed 13 Dec 2019].
Smolen, 2019, Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study, Lancet, 393, 2303, 10.1016/S0140-6736(19)30419-2
European Medicines Agency . Increased risk of blood clots in lungs and death with higher dose of Xeljanz (tofacitinib) for rheumatoid arthritis, 2019. Available: https://www ema europa eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis
Smolen, 2016, Head-To-Head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, The Lancet, 388, 2763, 10.1016/S0140-6736(16)31651-8
Verschueren P , Emery P , van Hoogstraten H , et al . THU0215 efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. Ann Rheum Dis 2018;77:A327.
Tanaka, 2013, Discontinuation of biologics in patients with rheumatoid arthritis, Clin Exp Rheumatol, 31, S22
Tanaka, 2019, The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis, Arthritis Res Ther, 21, 164, 10.1186/s13075-019-1937-4
Smolen, 2018, Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the preserve trial, Arthritis Res Ther, 20, 8, 10.1186/s13075-017-1484-9
Tweehuysen, 2017, Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review, Arthritis Rheumatol, 69, 301, 10.1002/art.39946
Smolen, 2020, Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis, Rheumatology, 59, 153, 10.1093/rheumatology/kez224
Bouman CAM , den Broeder AA , van der Maas A , et al . What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors? RMD Open 2017;3:e000327.doi:10.1136/rmdopen-2016-000327
ten Wolde, 1996, Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis, The Lancet, 347, 347, 10.1016/S0140-6736(96)90535-8
del Rincón, 2014, Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis, Arthritis & Rheumatology, 66, 264, 10.1002/art.38210
Landewé, 2018, Overdiagnosis and overtreatment in rheumatology: a little caution is in order, Ann Rheum Dis, 77, 1394, 10.1136/annrheumdis-2018-213700
Bécède, 2019, Risk profiling for a refractory course of rheumatoid arthritis, Semin Arthritis Rheum, 49, 211, 10.1016/j.semarthrit.2019.02.004